Articles 10.18.2023 Cognito Therapeutics to Present Phase 2 OVERTURE Study Open-Label Extension Data Showing Safety and Durability of Treatment Benefits Over 18 Months at CTAD 2023 Business Wire Share Article
Cognito Shares HOPE Study Results at CTAD Business Wire 11.16.2026 Read More: Cognito Shares HOPE Study Results at CTAD
Cognito Expands Executive Leadership Team Business Wire 11.12.2026 Read More: Cognito Expands Executive Leadership Team
Rhode Island Life Science Hub and Cognito Therapeutics Launch Brain Health Collaboratory to Advance Innovation in Alzheimer’s Disease PR Newswire 10.13.2026 Read More: Rhode Island Life Science Hub and Cognito Therapeutics Launch Brain Health Collaboratory to Advance Innovation in Alzheimer’s Disease